NCT02285088View on ClinicalTrials.gov

A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

May 31, 2017

Conditions
Healthy SubjectsSickle Cell Disease
Interventions
DRUG

GBT440

GBT440 will be administered as oral capsules

DRUG

Placebo

Matching placebo will be administered as oral capsules

Trial Locations (1)

SE1 9RT

Guy's Hospital, London

Sponsors
All Listed Sponsors
lead

Global Blood Therapeutics

INDUSTRY